Um modelo de inferência para a classificação de resultados processuais da Justiça Estadual

Este artigo tem como objetivo apresentar um modelo de inferência para classificar processos jurídicos relacionados à Justiça Estadual utilizando dados documentados de jurisprudência, tais como: comentários dos juízes realizados durante os veredictos, classes jurídicas do processo e UF. Os dados foram extraídos de websites de cortes judiciais, como o Portal do Tribunal de Justiça do Estado de Minas Gerais e o Poder Judiciário do Estado de Alagoas. Em toda a base de dados, foi realizada uma seleção no campo textual da descrição da sentença para extrair as leis que foram consideradas nos veredictos. Para tal seleção, o atributo de publicação e a quantidade de ocorrências da lei na base de dados foram considerados. As técnicas utilizadas para realizar a mineração de dados e classificar os processos como procedentes ou improcedentes foram a árvore de decisão e as redes neurais artificiais. Os testes realizados mostraram resultados satisfatórios e superiores ao valor comum para classificação de dados de jurisprudência, de normalmente 60%

Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members

Background: This study aimed at investigating antiepileptic drug (AED) prescription preferences in patients with brain tumor-related epilepsy (BTRE) among the European neuro-oncology community, the considerations that play a role when initiating AED treatment, the organization of care, and practices with regard to AED withdrawal.  Methods: A digital survey containing 31 questions about prescription preferences of AEDs was set out among members of the European Association of Neuro-Oncology (EANO).  Results: A total of 198 respondents treating patients with BTRE participated of whom 179 completed the entire survey. Levetiracetam was the first choice in patients with BTRE for almost all respondents (90% [162/181]). Levetiracetam was considered the most effective AED in reducing seizure frequency (72% [131/181]) and having the least adverse effects (48% [87/181]). Common alternatives for levetiracetam as equivalent first choice included lacosamide (33% [59/181]), lamotrigine (22% [40/181]), and valproic acid (21% [38/181]). Most crucial factors to choose a specific AED were potential adverse effects (82% [148/181]) and interactions with antitumor treatments (76% [137/181]). In the majority of patients, neuro-oncologists were involved in the treatment of seizures (73% [132/181])). Other relevant findings were that a minority of respondents ever prescribe AEDs in brain tumor patients without epilepsy solely as prophylaxis (29% [53/181]), but a majority routinely considers complete AED withdrawal in BTRE patients who are seizure-free after antitumor treatment (79% [141/179]).  Conclusions: Our results show that among European professionals treating patients with BTRE levetiracetam is considered the first choice AED, with the presumed highest efficacy and least adverse effects

Supratotal Resection of Glioblastoma: Is Less More?

N/